Posted by Michael Wonder on 11 Oct 2022
PHARMAC considering more options for people with inflammatory bowel disease
11 October 2022 - PHARMAC has initiated consultation today to fund ustekinumab (Stelara) for people with inflammatory bowel disease and to widen access to infliximab (Remicade) for inflammatory bowel disease-associated arthritis.
“Following the budget increase, we are working our way through our options for investment list,” says Pharmac’s chief executive Sarah Fitt. “Since 1 July 2022, we’ve funded 3 new treatments, widened access to 14 and are currently considering consultation feedback on 11 proposals. We are pleased to be using this opportunity to progress the funding of many more treatments.”
